CD59-Regulated Ras Compartmentalization Orchestrates Antitumor T-cell Immunity.

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• T cell-mediated immunotherapy shows promise but has limited efficacy.
• The Ras/MAPK pathway is crucial for T-cell development, proliferation, and function.
• Understanding T-cell immune responses requires a broader perspective.

Purpose of the Study:

• To investigate the role of intracellular CD59 in T-cell activation and function.
• To explore the relationship between CD59, Ras transport, and the Ras/MAPK pathway.
• To evaluate CD59 as a target for T cell-mediated cancer immunotherapy.

Main Methods:

• Analysis of intracellular CD59 localization and expression in T cells from cancer patients.
• Investigating the interaction between CD59 and Ras in T cells.
• Utilizing mouse models with CD59 deficiency (mCd59ab) to assess tumor growth and metastasis.
• Employing bone marrow transplantation and T-cell depletion assays.
• Assessing MAPK signaling and T-cell activation in human T cells with reduced CD59 expression.

Main Results:

• Intracellular CD59 facilitates Ras transport to the plasma membrane; deficiency leads to Ras accumulation in the Golgi.
• CD59 deficiency enhances Ras/MAPK signaling, T-cell activation, proliferation, and function.
• mCd59ab deficiency in mice significantly inhibited tumor growth and metastasis.
• Increased CD4+ and CD8+ T cells were observed in mCd59ab-deficient mice, inversely correlating with tumor burden.
• Reduced CD59 expression boosted MAPK signaling and T-cell activation in human T cells.

Conclusions:

• Subcellular compartmentalization of Ras by intracellular CD59 regulates T-cell activation.
• CD59 deficiency potentiates T-cell-mediated antitumor immunity.
• Targeting intracellular CD59 represents a potential strategy for T cell-mediated cancer immunotherapy.